Author

MiRa Huyghe

Observed name: M Huyghe

Institution: Spyre Therapeutics (United States)

Observed institution: Spyre Therapeutics (United States)

OpenAlex ID: A5111964981

Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury

2006 · ES Baskin-Bey, K Washburn, et al. · American Journal of Transplantation · 180

P0978 SKYLINE-UC: The First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-Acting Antibodies Administered as Single Agents and in Combinations

2026 · S Danese, V Jairath, et al. · Journal of Crohn s and Colitis · 1

Su1871: INTERIM PK DATA FOR SPY001, A NOVEL HALF-LIFE EXTENDED MONOCLONAL ANTIBODY TARGETING α4β7, SUGGEST A POTENTIAL FOR Q3M OR Q6M MAINTENANCE DOSING FOR INFLAMMATORY BOWEL DISEASE

2025 · Deanna Nguyen, Li Yan, et al. · Gastroenterology · 1

Tu1469 INTERIM PHASE 1 RESULTS FOR SPY003, A NOVEL HALF-LIFE EXTENDED MONOCLONAL ANTIBODY TARGETING IL-23, SUGGEST POTENTIAL FOR Q3M OR Q6M MAINTENANCE DOSING FOR INFLAMMATORY BOWEL DISEASE

2026 · Yulia Vugmeyster, Rachel McLean, et al. · Gastroenterology

Tu1469 INTERIM PHASE 1 RESULTS FOR SPY003, A NOVEL HALF-LIFE EXTENDED MONOCLONAL ANTIBODY TARGETING IL-23, SUGGEST POTENTIAL FOR Q3M OR Q6M MAINTENANCE DOSING FOR INFLAMMATORY BOWEL DISEASE

2026 · Yulia Vugmeyster, Rachel McLean, et al. · Gastrointestinal Endoscopy

P0834 Interim Phase 1 Results for SPY003, a Novel Half-life Extended Monoclonal Antibody Targeting IL-23, Suggest a Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease

2026 · Y Vugmeyster, R McLean, et al. · Journal of Crohn s and Colitis

Works count: 6

Citation count: 182

H-index: 1

I10-index: 1